JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know

Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.

Zacks Equity Research

2 min read

Shares of Janux Therapeutics JANX have risen 19.1% over the past three months, driven by continued progress across its clinical pipeline and a series of upcoming catalysts.

The company is making steady progress across its oncology and immunotherapy pipeline, led by its three proprietary tumor-activated core platforms, including Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr) and Adaptive Immune Response Modulator (ARM). The company’s pipeline comprises several wholly owned assets, notably JANX007, JANX014, JANX011 and JANX013.

Year to date, JANX shares have risen 25.3% compared with the industry’s 12.9% growth.

Image Source: Zacks Investment Research

Progress Across Prostate Cancer Programs

Janux’s lead prostate cancer candidate, JANX007, remains a major driver of investor interest. The prostate-specific membrane antigen (PSMA)-targeted TRACTr is being evaluated in a phase Ib study in metastatic castration-resistant prostate cancer (mCRPC), with continued enrollment, dose optimization and expansion in taxane-naïve patients. The company is evaluating JANX007 in combination with darolutamide to improve outcomes in earlier-stage mCRPC patients. Additional data on JANX007 is expected in the first half of 2027. This combination strategy could broaden the potential clinical utility of JANX007 and strengthen its positioning within the competitive prostate cancer treatment landscape.

In April, the company initiated patient dosing in a phase I study evaluating JANX014, a next-generation double-masked PSMA TRACTr program designed to enhance tumor selectivity and safety in prostate cancer.

Autoimmune Pipeline Creates a Second Growth Opportunity

Beyond oncology, Janux is expanding into autoimmune diseases with JANX011, a CD19-targeted ARM. The candidate is currently being evaluated in an early-stage clinical study in healthy volunteers, with dosing underway. The company expects to provide initial clinical data from the study in the second half of 2026.

The company continues to advance additional TRACTr, TRACIr and ARM programs for potential future development. Janux intends to begin clinical development of JANX013, a PSMA-targeted CD28 costimulatory TRACIr candidate, later in 2026. The candidate is designed to be administered in combination with JANX007.

Beyond these wholly owned pipeline candidates, Janux has strategic collaborations with Merck & Co. MRK and Bristol Myers Squibb BMY to develop novel tumor-activated therapies using the TRACTr platform. Under the agreement with BMY, the companies are expected to develop a novel, tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types.

Janux initiated patient dosing in its TRACTr collaboration program with MRK (known as MSD outside the United States and Canada) in August 2025 and remains eligible for future milestone payments and royalties tied to the program’s development and commercialization.

Strong Balance Sheet Reduces Financing Risk

JANX ended the second quarter of 2026 with $970.9 million in cash, cash equivalents and short-term investments. At the same time, the company's quarterly net loss narrowed substantially year over year due to lower operating expenses. The combination of a large cash balance and lower quarterly losses give Janux considerable flexibility to continue investing in its clinical programs.

Janux Therapeutics, Inc. Price and Consensus

Janux Therapeutics, Inc. price-consensus-chart | Janux Therapeutics, Inc. Quote

JANX's Zacks Rank

Janux currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

See Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report